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Abstract
This paper reviews the current literature on smoke inhalation injuries with special attention to the effects of
hydrogen cyanide. It is assumed that cyanide poisoning is still an overlooked diagnosis in fire victims. Treatment
against cyanide poisoning in the emergency setting should be given based on the clinical diagnosis only. Oxygen
in combination with a recommended antidote should be given immediately, the first to reduce cellular hypoxia
and the second to eliminate cyanide. A specific antidote is hydroxycobalamin, which can be given iv. and has few
side effects.
The most common occurrence of cyanide
poisoning
Several reports have shown that persons admitted to
hospital due to fire accidents may have been exposed to
carbon monoxide (CO) as well as cyanide (CN) [1-3]. In
fact, it has been reported that the most common source
of CN poisoning in humans arise from exposure to fires
[4]. In fires CN is developed when the temperature
reaches 315°C (600°F) and is released from the toxic
fumes in the gaseous form, i.e. hydrogen cyanide (HCN)
which may then be inhaled by the victim [1]. HCN is
developed from an incomplete combustion of any mate-
rial containing nitrogen [5] such as plastic, vinyl, wool
or silk [6]. It is worth noticing that when cotton burns
it develops 130 μg HCN/g, paper 1100 μgH C N / ga n d
wool 6300 μg HCN/g. One has to be aware that HCN is
still produced when the fire is only glowing embers [7].
Symptoms of cyanide poisoning
HCN is easily absorbed from all routes of exposure [8].
Since CN is a small lipid soluble molecule and mainly
undissociated, distribution and penetration of CN into
cells is rapid. CN can be distributed in the body within
seconds and death can occur within seconds or minutes
after a large dose [9,10]. Initially, the symptoms include
a brief period of hyperpnoea, due to direct stimulation
of the chemo receptors of the carotid and aortic bodies
by CN [11]. CN also stimulates the nociceptors, leading
to a brief sensation of dryness and burning in the nose
and throat [12]. In milder cases of CN poisoning the
symptoms are headache, nausea, vertigo, anxiety, altered
mental status, tachypnea, hypertension and there may
be an odour of bitter almonds in the patients expiration.
In more severe cases the patient will have dyspnoea, bra-
dycardia, hypotension and arrhythmia. In most severe
cases the patients symptoms are unconsciousness,
convulsions, cardiovascular collapse followed by shock,
pulmonary oedema and death [6]. Death is due to
respiratory arrest but the heart invariably outlasts
respiration and may continue to beat for as long as
3-4 min. after the last gasp [8,12].
Virtually all patients with severe, acute CN poisoning
die immediately. Autopsy findings include petechial,
subarachnoid or subdural haemorrhages [13]. As very
few people survive severe CN poisoning, reports of late
neurological sequelae are rare.
CN poisoning in mild degrees is recognized as a cause
of permanent neurological disability, ranging from var-
ious extrapyramidal syndromes to post-anoxic vegetative
states [14]. Most cases develop over many years. Both
parkinsonian symptoms and a dystonia syndrome have
been observed [15-18].
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The similarity between CO and CN is the ability to bind
iron ions. However, where CO impairs the ability of ery-
throcytes to transfer oxygen, CN binds to erythrocytes
but does not affect the oxygen transfer. Both CO and
CN affect the mitochondria by binding to the enzyme
cytochrome-c oxidase a, a3 (CCO), the terminal enzyme
complex of the respiratory chain in complex IV [10].
T h ea c t i v e( O 2-binding) site of CCO is binuclear, con-
sisting of heme a3 and CuB [19]. CO binds to the
r e d u c e df o r mo fC C Oa n dC Nb i n d st oe i t h e rt h e
reduced CCO heme (Fe
2+)o ro x i d i z e dh e m e( C u B
2+)
[20-22]. The primary effect of CN is a blocking of the
mitochondrial respiration chain and the formation of
intracellular adenosine triphosphate (ATP) [10]. The
result is cytotoxic hypoxia caused by the inhibition of
CCO by the high affinity of CN to heme a3 of the
enzyme. The effect is a structural change and a reduced
activity of the enzyme and an increase in lactate produc-
tion resulting in metabolic acidosis [23,24].
Diagnosis
CN poisoning seems to be an overlooked diagnosis in fire
victims. In 1991, Baud showed that persons from fire
accidents were poisoned by both CN and CO [25]. The
diagnosis of CN poisoning presents a dilemma for first-
response emergency personnel. Clinicians are often able
to diagnose CO poisoning by either arterial- or venous
blood sampling measuring carboxyhaemoglobin or by
oximetry although the latter may be unreliable [26].
Diagnosing CN poisoning however, remains a challenge
in the emergency setting. At the same time immediate
treatment is of outmost importance. Given the fact that
methods to detect and measure CN in blood are usually
not readily available and that patients may often be
exposed to both CO and CN, clinicians have to rely on
the presenting symptoms and the general clinical status
of the patient. In patients hospitalised with a history of
fire accident, combined with severe neurological symp-
toms such as reduced Glasgow Coma Scale (GCS) Scor-
ing and either soot particles in the mouth or tracheal
expectoration, is likely to be an indicator of concomitant
CN poisoning [23]. Baud et al. found that the concentra-
tion of lactate increases proportionally with the amount
of CN poisoning because of the metabolic acidosis [27].
Based on these observations and given the fact that
whole blood CN measurements may not be available,
the patient admitted to hospital after exposure to fire
combined with smoke inhalation injuries, supplementary
CN intoxication should be suspected if two or more of
the following criteria are fulfilled:
1) Signs of neurological incapacitation such as altered
mental status, unconsciousness and convulsions
2) Soot in the mouth or expectoration
3) Fire accident patents where arterial blood sampling
reveal metabolic acidosis with a lactate above 8 mmol/l
as the concentration of lactate increases proportional
with the rate of CN poisoning. A lactate of 10 mmol/l is
a sensitive and specific indicator of CN intoxication [23].
Currently, two methods of whole blood CN analysis
dominates the literature:
One method is the Conway/microdiffusion method
where test material is whole blood. CN is liberated from
the blood into the gas phase and subsequently bound to
hydroxycobalamin (OHCob) forming cyanocobalamin
(CNCob). The concentration of CNCob can be read my
means of a spectrophotometer [28]. Results are available
within a 2-h period.
The other method is isotope-dilution gas chromato-
graphy-mass spectrometry (ID GC/MS) that is an auto-
mated procedure where test material is whole blood.
Samples are prepared and analysed within a 2-h period
[29].
With the current available methods for the analysis of
CN blood concentrations, one may conclude that in the
clinical setting it takes hours before a result may be
available for the treating doctor [30]. Furthermore, CN
is an unstable molecule and has an elimination half-life
of 1 hour in blood in vivo. Therefore determination of
CN in blood requires rapid sampling and analysis
[25,27].
Treatment
The treatment of CN poisoning is aiming at basic life
support including 100% oxygen, assisted ventilation if
the patient is unconscious (GCS < 8) or the airway
seems compromised, decontamination, correction of
acidosis and blood pressure support [31,32] combined
with the use of an antidote. Currently there are four
types of antidotes. These include OHCob, sodium thio-
sulfate, dicobalt edetate and methaemoglobin forming
antidotes. Initial evaluation of antidotal efficacy is based
on correction of hypotension and lactic acidosis and the
final outcome rests on the degree of permanent central
nervous system injury [33]. The different antidotes shall
be described briefly here below.
OHCob has a rapid onset of action as it dissolves into
the different tissue compartments almost immediately
when administered by infusion [34]. It has the advantage
of not interfering with tissue oxygenation [35] and in
both human and animal studies it has been shown to
improve hemodynamic stability [34,36-38]. OHCob acts
by covalent binding to CN and forms cyanocobalamin
(CNCob) which is B12 vitamin [39,40]. CNCob is
excreted through the kidneys [41]. Given iv. OHCob dis-
tributes to the erythrocytes and plasma cells and after
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effects are red colouring of skin and urine, urticarial
eczema and seldom anaphylactic chock [32]. In a series
of normal human volunteers given 5 g of OHCob iv.
during 20 minutes, a mild, transient, self-limiting hyper-
tension accompanied by reflex bradycardia has been
reported [38]. OHCob must not delay any other basic
life support such as securing of the airways, cardiovascu-
lar support or oxygen supply [31,32]. OHCob in blood
interferes with CO-oximetry measurements of COHb,
methemoglobin (MetHb), and Hb-O2.T h i sm u s tb e
considered during OHCob treatment, particularly in
smoke inhalation victims with concurrent CO exposure,
because it may lead to potentially erroneous reported
COHb levels. OHCob will cause an increase in mea-
sured COHb percentage values [43].
Sodium thiosulfate removes CN from the blood
through the action of rhodanese [44]. Rhodanese is an
enzyme located in the mitochondria mainly in the liver,
kidney and skeletal muscles [45,46]. It adds a sulphur
atom to CN and forms thiocyanate which is less toxic
and excreted through the kidneys [47,48]. Sodium thio-
sulfate has limited distribution into the brain as well as
limited penetration into the mitochondria, where the
endogenous rhodanese is located [40,49]; accordingly
sodium thiosulfate exerts its main effect in blood and
plasma [50]. Sodium thiosulfate has a slow onset of
action [6]. Less significant side effects such as nausea,
vomiting, and injection site pain, irritation, and a burn-
ing sensation has been reported [39,51]. There is limited
information available about the efficacy of sodium thio-
sulfate for treatment of CN poisoning [35]. No clinical
trials of sodium thiosulfate are available, and efficacy
has been extrapolated from case studies and series of
acute CN poisoning.
Dicobalt EDTA is an efficient antidote with a high
affinity to CN but it has restricted use. The mechanism
of action is chelation of CN to form the much less toxic
cobalt cyanide. Dicobalt EDTA has deleterious cardio-
vascular side effects and is often poorly tolerated. To
mitigate these side effects intravenous glucose should be
co administered during treatment. The side effects are
enhanced if the patient is not CN poisoned so it should
be used only in very severe cases where the diagnosis is
certain [32,35,40].
Amyl nitrite and sodium nitrite are methemoglobin
forming antidotes, which are relatively contraindicated
in smoke inhalation. Nitrite reduces blood CN by form-
ing methemoglobin, to which CN binds with higher affi-
nity than it does to CCO. Significant side effects such as
vasodilatation and hypotension are seen during treat-
ment. Induction of methemoglobin forming antidote
treatment has the potential to impair the oxygen carry-
ing capacity of haemoglobin [6]. In the smoke inhalation
victim, with concomitant COHgb increase and possible
pulmonary injury, there is an obvious added risk asso-
ciated with methemoglobin formation [6].
Adjunctive treatment of CN intoxication
Hyperbaric oxygen therapy (HBO) is recommended by
UHMS as an adjunct to the treatment of CO poisoning
complicated by CN poisoning [52]. HBO has been
shown to improve survival and improve tissue oxygena-
tion in the clinical as well as in the experimental set-
tings [53] and HBO is recommended especially when
supportive measures and other CN antidotes fail
[54-56]. Several studies have demonstrated a protective
effect of HBO therapy in experimental ischemic brain
injury, and many physiological and molecular mechan-
isms of HBO therapy-related neuroprotection have been
identified [57]. Also HBO has been shown to reduce the
risk of cognitive sequelae after acute CO poisoning
when HBO is given within a 24-hour period [58].
Furthermore it has been shown that HBO increases the
flexibility of red blood cells (thereby improving micro-
circulatory perfusion), reduces tissue oedema and pre-
serves intracellular ATP [59-62]. The binding of CN to
CCO is most often referred to as being irreversible
[23,32]. However, recent evidence suggests that CN
binding to CCO is reversible. Where CN binding to
CCO appears to be independent of the oxygen tension,
there seems to be a competition between CN and nitric
oxide (
￿NO). High concentrations of
￿NO have been
found to attenuate the inhibition of CCO induced by
CN and CO [63,64]. In keeping with this, HBO therapy,
but not normobaric oxygen, has been shown to increase
the bioavailability of
￿NO [65-69] which may show to be
beneficial during CN poisoning. Whether HBO therapy
holds any place in the treatment of acute CN poisoning
when readily available is a matter of continued debate.
In keeping with the above and the fact that patients
from fires are both CO and CN poisoned we recom-
mend HBO as well where safely available.
Conclusion
Treatment of suspected CN poisoning presents a
dilemma for medical first-response emergency person-
nel, as clinicians are often unable to diagnose CN poi-
soning in the emergency setting. Immediate treatment is
of outmost importance. In summary immediate treat-
ment includes 100% oxygen, assisted ventilation if the
patient is unconscious (GCS < 8) or the airway seems
compromised, decontamination, correction of acidosis
and blood pressure support [31,32]. Antidotes include
OHCob, sodium thiosulfate, di-cobalt EDTA and
methaemoglobin-inducers. Currently, there is no inter-
national agreement of which antidote is the preferred to
use but OHCob and sodium thiosulfate seem to be
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an attractive antidote due to its rapid CN binding and
its lack of serious side effects, even in the absence of
CN intoxication. Accordingly this is the recommended
antidote treatment in Denmark to known or suspected
CN poisoning. In France OHCob is given prehospital by
EMS personnel but not in Denmark, as the Health Min-
istry has not approved it for this use [70].
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